Home » Archive by Category

News

San Diego biotech news from BioSpace, Xconomy, PR Newswire, Marketwired and other sources, click on headlines to read the full story.

Irvine Pharmaceutical Services Announces the Opening of an Analytical Facility in Hangzhou, China

October 30, 2014 – 8:25 am | Edit Post

IRVINE, Calif., Oct. 30, 2014 /PRNewswire/ – Irvine Pharmaceutical Services, Inc., a leading provider in cGMP contract development and parenteral manufacturing services, announces plans to open a new facility in Hangzhou, China. This 115,000sqft. newly built, state-of-the-art facility will expand Irvine’s service offerings into the Asian markets.

Irvine’s newest facility is scheduled to be fully operational in the first quarter of 2015. CEO and Founder, Dr. Assad J. Kazeminy explains, “Irvine is responding to the rising needs of large multi-national pharmaceutical companies that are looking for contract organizations overseas that include robust cGMP quality infrastructure and technical expertise. Irvine will now have a local presence and a strong understanding of the local market to offer the region high quality analytical support.”

Learn more about Irvine’s expansion into the Asian market – Visit us at booth 3110 at the 2014 AAPS Annual Meeting and Exposition in San Diego, CA on November 2 – 6, 2014.

About Irvine

Irvine Pharmaceutical Service Inc. is a premier contract development and manufacturing organization providing support to the pharmaceutical, biopharmaceutical, and medical device industries. Irvine provides cGMP contract development and manufacturing services such as parenteral manufacturing (liquid and lyophilized), preformulation/formulation development, analytical development, biopharmaceutical development, stability storage, analytical chemistry, structural chemistry, microbiology, and drug delivery device testing.

Learn more at www.irvinepharma.com or call (949) 951-4425.
SOURCE Irvine Pharmaceutical Services, Inc.

Promising Data Presented at the Chicago Multidisciplinary Symposium on Thoracic Oncology From an Investigator-Sponsored Trial of Peregrine Pharmaceuticals’ Bavituximab in Combination With Pemetrexed and Carboplatin in Front-Line Non-Small Cell Lung Cancer

October 30, 2014 – 6:41 am | Edit Post

Promising Data Presented at the Chicago Multidisciplinary Symposium on Thoracic Oncology From an Investigator-Sponsored Trial of Peregrine Pharmaceuticals’ Bavituximab in Combination With Pemetrexed and Carboplatin in Front-Line Non-Small Cell Lung Cancer

The Coming of Age of Stem Cell Therapy

October 30, 2014 – 6:00 am | Edit Post

In 2004, the therapeutic potential of stem cells persuaded more than 7 million Californians to approve Proposition 71, which allocated a whopping $3 billion for research and development of stem cell-based drugs and therapies that might someday address a medical dictionary’s worth of diseases and conditions.

York Hall Science Labs Get $6.5 Million Makeover to Help Students Graduate in Four Years

October 30, 2014 – 6:00 am | Edit Post

Four undergraduate teaching laboratories for biology and chemistry students have undergone a $6.5 million makeover as part of implementation of the UC San Diego Strategic Plan. The renovated labs in York Hall will eliminate a key barrier to students accessing impacted laboratory science courses—making it easier for them to graduate in four years.

California Brain Research Program Launched

October 30, 2014 – 6:00 am | Edit Post

Cal-BRAIN—a statewide research grants program that aims to revolutionize our understanding of the brain—is officially underway. The first call for proposals has gone out, and the program expects to announce its first awards in early 2015.

The Coming of Age of Stem Cell Therapy

October 30, 2014 – 6:00 am | Edit Post

In 2004, the therapeutic potential of stem cells persuaded more than 7 million Californians to approve Proposition 71, which allocated a whopping $3 billion for research and development of stem cell-based drugs and therapies that might someday address a medical dictionary’s worth of diseases and conditions.

Auspex Pharmaceuticals Initiates Second Pivotal Clinical Trial For SD-809 In Tardive Dyskinesia

October 30, 2014 – 5:00 am | Edit Post

LA JOLLA, Calif., Oct. 30, 2014 (GLOBE NEWSWIRE) — Auspex Pharmaceuticals, Inc. (Nasdaq:ASPX), a biopharmaceutical company dedicated to developing innovative medicines for people with movement disorders and other rare diseases, today announced the enrollment of the first patient in a multi-center Phase…

Alphatec Spine To Showcase New Arsenal Spinal Fixation System At The Upcoming 29th Annual North American Spine Society Meeting In San Francisco

October 30, 2014 – 5:00 am | Edit Post

CARLSBAD, Calif., Oct. 29, 2014 (GLOBE NEWSWIRE) — Alphatec Holdings, Inc. (Nasdaq:ATEC), the parent company of Alphatec Spine, Inc., a global provider of spinal fusion technologies, announced today that it will showcase its new spinal fixation system, Arsenal as well as its comprehensive portfolio…

Aptose Biosciences To Host Conference Call And Webcast For Four Month Interim Period Ended September 30, 2014

October 30, 2014 – 5:00 am | Edit Post

SAN DIEGO and TORONTO, Oct. 30, 2014 /PRNewswire/ – Aptose Biosciences Inc. (Aptose) (NASDAQ: APTO; TSX:APS), a clinical-stage company developing targeted agents and molecular diagnostics to treat the underlying mechanisms of cancer, today announced it intends…

Immunomedics, Inc. Provides Update On Phase 2 Study Of Isactuzumab Govitecan In Patients With Diverse Metastatic Solid Cancers

October 30, 2014 – 5:00 am | Edit Post

SAN DIEGO, Oct. 29, 2014 (GLOBE NEWSWIRE) — Immunomedics, Inc., (Nasdaq:IMMU) today announced that isactuzumab govitecan (IMMU-132), the Company’s proprietary solid-tumor antibody-drug conjugate (ADC), continues to produce encouraging results in a Phase 2 clinical trial in heavily…